Kythera Biopharmaceuticals purchases global rights to Setipiprant, a PGD2 antagonist

Update: Kythera audio interview with founder and CEO Keith Leonard regarding Setipiprant and the company’s recent history of hair loss research is now out.  Excellent stuff!

=================================================

A thus far barren February when it comes to significant hair loss research related new developments suddenly changed drastically today with the announcement that Kythera Biopharmaceuticals (US) has purchased global rights to Setipiprant, a clinical-stage oral antagonist to the prostaglandin D2 (PGD2) receptor.  The shareholder presentation on this is a must read.  Rights were purchased via licensing agreements with Actelion Pharmaceuticals (Switzerland) and the University of Pennsylvania.  A good summary is here, with a very encouraging quote from Kythera’s Chief Medical Officer:

Setipiprant is believed to directly affect this hair loss pathway, and our own preclinical and in vitro human hair models confirmed this effect. It is a well-characterized molecule with a large safety database and we believe we can quickly initiate a development program to study it in hair loss.

According to the investor presentation, Setipiprant has already undergone 8 clinical trials, including:

  • a Phase III study in seasonal allergic rhinitis patients.
  • a Phase IIB proof of concept study in asthma patients.
  • and it has a safety database of over 1,000 subjects.

One other item in the investor presentation that I found shocking (in a very good way) was that Actelion has 48 patents and patent application of which 45 were granted for molecules that inhibit PGD2!  So Setipiprant is just one molecule of perhaps dozens or even hundreds that can inhibit PGD2.  There must be other companies that also have patents to proprietary PGD2 antagonist molecules, but I wonder if they can introduce their products into the hair loss market in future if they do not have licensing agreements with the University of Pennsylvania?

PGD2 has been in the news a lot in the hair loss world during the past several years, in large part due to Dr. Luis Garza’s (and Ashley Nieves’) work and excellent publicly available 2014 paper on the subject, as well as past work of Dr. George Cotsarelis and his team at the University of Pennsylvania.  Both Cotsarelis and Garza were part of a large group of authors of an important 2012 paper which concluded that PGD2 inhibits hair growth and was elevated on the scalps of balding men.  Together, these two men are also considered to be co-inventors/co-founders of this PGD2-receptor pathway that inhibits hair growth.  The patent for this technology is owned by the University of Pennsylvania, hence their involvement in this current transaction.

It seems like the PGD2-GPR44 pathway (PGD2 binds to the GPR44 receptor) is responsible for hair growth inhibition, and any drug to regrow hair will target GPR44.  More significantly, PGD2 is also involved in asthma, allergies and related medical disorders. In fact a number of drugs targeting PGD2 are already in advanced clinical trials or even on the market, so there should already be a good deal of safety information on this type of product.

I found seven studies on Setipiprant on Pubmed as of today.  Also, some popular media articles from 2012 on PGD2 and a hair loss cure are worth a reread: Dailymail,  The Telegraph and NY Times. Unfortunately we are still not close to getting a topical lotion cure, since Setipiprant is an oral medication.

For the often neglected female readers of this blog, it seems like there is a very good chance that this same drug could also cure female pattern hair loss.  PGD2 appears to curtail hair growth in both men and women.

Finally, a bit about Los Angeles area (where else would one expect a biopharma company to focus on eliminating double chins?) based publicly traded Kythera from their website:

Our product candidate, ATX-101, is a potential first-in-class, injectable drug currently in late-stage clinical development for the reduction of submental fat, which commonly presents as an undesirable “double chin.” We maintain an active research interest in hair and fat biology, pigmentation modulation and facial contouring.

One-year stock price trend of ticker KYTH.

13 thoughts on “Kythera Biopharmaceuticals purchases global rights to Setipiprant, a PGD2 antagonist”

  1. Admin, they are presenting at the 2015 Leerink Global Healthcare Conference. They are livestreaming it tomorrow at 10am on their website on the investor page. I’d be interested in knowing they’ll say anything about it. I think it’s entirely possible since this news broke today, and they agreed to go to this conference awhile ago.

    Here’s the link: http://investors.kytherabiopharma.com/

  2. Hola administrador, cree usted que el desarrollo de un producto podría aparecer prontamente??? o tendremos que esperar varios años mas??? me gustaría conocer su opinión.

    1. Diego, dudo nada en menos de 2 a 3 años. Sin embargo, como con dutasterida, tal vez las personas tendrán acceso al producto sin que sea aprobado por la FDA.

      1. Gracias por su respuesta administrador. Quiero ver si me puede ayudar con algo que me está pasando a mi y seguro a varios de este blog. Estamos en años decisivos si va a salir algo nuevo para la alopecia. Yo estoy en la duda si hacerme cirugía o no ya que según me respondió Replicel y su vicepresidente un producto llegaría en 2017, osea en 2 años. Pero me genera dudas respecto a los resultados, si va a regenerar y si se va a poder mantener en el tiempo. Según ellos van a ser permanentes y para los cabellos regenerados adelante seguramente va a necesitar mantenimiento. Usted sabe que va a llegar primero??? una medicación??? Replicel??? Histogen??? nadie dice nada y todavía no inician la fase 2. Usted que opina???? la cirugia no es la solución pero es lo unico que hay hoy en día.

        1. Diego.. te lo digo desde el fondo del alma.. no te hagas un transplante ya que habras gastado todo ese dinero en algo que por lo que poco a poco se va viendo.. no es en absoluto una opcion que dura la vida entera.. mas bien unos 15 años.. no te has dado cuenta de que se les recomienda a los pacientes que tienen un transplante que se tomen finasteride? por que no son de por vida los resultados.. si de verdad te haces un transplante.. que sea en un par de años cuando se mejore la tecninca aun mas y la cicatrizacion sea nula…piensalo… si quieresun trasnplante decente necesitas ir al 3% de los ciruganos dotados de la paciencia y la empatia como para hacer del transplante un exito…. sino vete a uno barato y veras lo que pasa…. a los 5 años tienes peor cabeza(por las cicatrizes) que cuando se esta calvo… haz mucha mucha indagacion en internet para ver d elo que hablo..

          1. hola Rowloboo, si tienes razón pero la parte psicologica me está matando. Te consulto cuantos años piensas tu que habrá que esperar para ver mejores resultados en transplantes de cabellos o tratamientos nuevos??? hace décadas que estamos esperando y siempre faltan 5 años. Te dejo una página de un cirujano prestigioso de mi país para ver si me podes dar tu opinión. Por favor te agradecería si sabes algo de él o me podes averiguar. Es el único que dicen que vale la pena.

            https://www.youtube.com/watch?v=B-ZB4VGBl6k

            http://injerto-capilar.com.ar/

            Espero respuesta. Gracias.

  3. Sounds promising and I like how they sound anxious to get things underway.

    It seems the molecule interrupts the process between DHT and miniaturization of the follicle, rendering DHT a non-issue (which is key to any treatment, imo, if it is to be more effective than minoxidil).

    Not sure how they can claim it’s “well tolerated” when a quarter of the people in this study http://investors.kytherabiopharma.com/ reported headaches from using it. Hopefully a larger sample size will reduce that percentage. My luck would be it would be the one treatment that finally works for me only to have to discontinue due to headaches from it.

    I’m also keeping my fingers crossed it turns out to be more effective for hair growth than it was for allergies.

  4. Alguien sabe si la mesoterapia con finasteride, minoxidil, buflometrina, pantenol y biotina da resultados???? algunos dermatologos la recomiendan.

Leave a Reply

Your email address will not be published. Required fields are marked *